Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENSOR: Selecting cancer patients for treatment using tumor organoids
2014-003811-13Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palbociclib, axitinib, selumetinib, gefitinib, glasdegib and 1 more in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) (8 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall clinical response rate (ORR) according to RECIST 1.1. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-003811-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003811-13.